{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:12:01Z","timestamp":1790860321421,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T00:00:00Z","timestamp":1323388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T00:00:00Z","timestamp":1323388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1038\/leu.2011.347","type":"journal-article","created":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T11:11:16Z","timestamp":1323429076000},"page":"977-984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib"],"prefix":"10.1038","volume":"26","author":[{"given":"J J W M","family":"Janssen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Deenik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K G M","family":"Smolders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B J","family":"van Kuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Pouwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G J","family":"Schuurhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G J","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,9]]},"reference":[{"key":"BFleu2011347_CR1","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"},{"key":"BFleu2011347_CR2","first-page":"182","volume":"112","author":"J Cortes","year":"2008","unstructured":"Cortes J, O\u2019Brien S, Borthakur G, Jones D, Ravandi F, Koller C et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). ASH Annu Meet Abstr 2008; 112: 182.","journal-title":"ASH Annu Meet Abstr"},{"key":"BFleu2011347_CR3","first-page":"446","volume":"112","author":"J Cortes","year":"2008","unstructured":"Cortes J, O\u2019Brien S, Jones D, Ferrajoli A, Konopleva M, Borthakur G et al. Efficacy of Nilotinib (formerly AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). ASH Annu Meet Abstr 2008; 112: 446.","journal-title":"ASH Annu Meet Abstr"},{"key":"BFleu2011347_CR4","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFleu2011347_CR5","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260\u20132270.","journal-title":"N Engl J Med"},{"key":"BFleu2011347_CR6","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994\u20131004.","journal-title":"N Engl J Med"},{"key":"BFleu2011347_CR7","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532\u20134539.","journal-title":"Blood"},{"key":"BFleu2011347_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"CH Jamieson","year":"2004","unstructured":"Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657\u2013667.","journal-title":"N Engl J Med"},{"key":"BFleu2011347_CR9","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/sj.leu.2404609","volume":"21","author":"X Jiang","year":"2007","unstructured":"Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926\u2013935.","journal-title":"Leukemia"},{"key":"BFleu2011347_CR10","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110: 4064\u20134072.","journal-title":"Blood"},{"key":"BFleu2011347_CR11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","volume":"108","author":"DL White","year":"2006","unstructured":"White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697\u2013704.","journal-title":"Blood"},{"key":"BFleu2011347_CR12","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","volume":"108","author":"NE Jordanides","year":"2006","unstructured":"Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC . Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006; 108: 1370\u20131373.","journal-title":"Blood"},{"key":"BFleu2011347_CR13","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/sj.leu.2404754","volume":"21","author":"A van Rhenen","year":"2007","unstructured":"van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S et al. Aberrant marker expression patterns on the CD34+. Leukemia 2007; 21: 1700\u20131707.","journal-title":"Leukemia"},{"key":"BFleu2011347_CR14","first-page":"1353","volume":"112","author":"M Terwijn","year":"2008","unstructured":"Terwijn M, Kelder A, Rutten AP, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ . Specific detection of aberrant and normal stem cells in acute myeloid leukemia patients opens the way for defining highly specific targets for stem cell therapy. ASH Annu Meet Abstr 2008; 112: 1353.","journal-title":"ASH Annu Meet Abstr"},{"key":"BFleu2011347_CR15","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","volume":"110","author":"A van Rhenen","year":"2007","unstructured":"van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007; 110: 2659\u20132666.","journal-title":"Blood"},{"key":"BFleu2011347_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1046\/j.1365-2141.2001.02927.x","volume":"114","author":"H Sutherland","year":"2001","unstructured":"Sutherland H, Blair A, Vercauteren S, Zapf R . Detection and clinical significance of human acute myeloid leukaemia progenitors capable of long-term proliferation in vitro. Br J Haematol 2001; 114: 296\u2013306.","journal-title":"Br J Haematol"},{"key":"BFleu2011347_CR17","first-page":"983","volume":"88","author":"MA van der Pol","year":"2003","unstructured":"van der Pol MA, Feller N, Roseboom M, Moshaver B, Westra G, Broxterman HJ et al. Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica 2003; 88: 983\u2013993.","journal-title":"Haematologica"},{"key":"BFleu2011347_CR18","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M . Chronic myeloid leukaemia. Lancet 2007; 370: 342\u2013350.","journal-title":"Lancet"},{"key":"BFleu2011347_CR19","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","volume":"112","author":"S Branford","year":"2008","unstructured":"Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330\u20133338.","journal-title":"Blood"},{"key":"BFleu2011347_CR20","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1056\/NEJM198306233082502","volume":"308","author":"L Coulombel","year":"1983","unstructured":"Coulombel L, Kalousek DK, Eaves CJ, Gupta CM, Eaves AC . Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 1983; 308: 1493\u20131498.","journal-title":"N Engl J Med"},{"key":"BFleu2011347_CR21","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3324\/haematol.2009.016766","volume":"95","author":"W Deenik","year":"2010","unstructured":"Deenik W, Janssen JJWM, van der HB, Verhoef GE, Smit WM, Kersten MJ et al. Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. Haematologica 2010; 95: 914\u2013921.","journal-title":"Haematologica"},{"key":"BFleu2011347_CR22","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041\u20136051.","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"BFleu2011347_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/stem.5530110924","volume":"11","author":"CJ Eaves","year":"1993","unstructured":"Eaves CJ, Cashman JD, Zoumbos NC, Barnett MJ, Eaves AC . Biological strategies for the selective manipulation of normal and leukemic stem cells. Stem Cells 1993; 11 Suppl 3: 109\u2013121.","journal-title":"Stem Cells"},{"key":"BFleu2011347_CR24","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1182\/blood.V79.4.1003.bloodjournal7941003","volume":"79","author":"CM Verfaillie","year":"1992","unstructured":"Verfaillie CM, Miller WJ, Boylan K, McGlave PB . Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992; 79: 1003\u20131010.","journal-title":"Blood"},{"key":"BFleu2011347_CR25","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/blood.V93.1.284","volume":"93","author":"M Delforge","year":"1999","unstructured":"Delforge M, Boogaerts MA, McGlave PB, Verfaillie CM . BCR\/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal. Blood 1999; 93: 284\u2013292.","journal-title":"Blood"},{"key":"BFleu2011347_CR26","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.V81.3.801.801","volume":"81","author":"T Leemhuis","year":"1993","unstructured":"Leemhuis T, Leibowitz D, Cox G, Silver R, Srour EF, Tricot G et al. Identification of BCR\/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood 1993; 81: 801\u2013807.","journal-title":"Blood"},{"key":"BFleu2011347_CR27","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1046\/j.1365-2141.2001.03027.x","volume":"114","author":"G Pratt","year":"2001","unstructured":"Pratt G, Rawstron AC, English AE, Johnson RJ, Jack AS, Morgan GJ et al. Analysis of CD34+ cell subsets in stem cell harvests can more reliably predict rapidity and durability of engraftment than total CD34+ cell dose, but steady state levels do not correlate with bone marrow reserve. Br J Haematol 2001; 114: 937\u2013943.","journal-title":"Br J Haematol"},{"key":"BFleu2011347_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1046\/j.1365-2141.2002.03373.x","volume":"117","author":"T Sumikuma","year":"2002","unstructured":"Sumikuma T, Shimazaki C, Inaba T, Ochiai N, Okano A, Hatsuse M et al. CD34+\/CD90+ cells infused best predict late haematopoietic reconstitution following autologous peripheral blood stem cell transplantation. Br J Haematol 2002; 117: 238\u2013244.","journal-title":"Br J Haematol"},{"key":"BFleu2011347_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000095872","volume":"116","author":"G Specchia","year":"2006","unstructured":"Specchia G, Pastore D, Mestice A, Liso A, Carluccio P, Leo M et al. Early and long-term engraftment after autologous peripheral stem cell transplantation in acute myeloid leukemia patients. Acta Haematol 2006; 116: 229\u2013237.","journal-title":"Acta Haematol"},{"key":"BFleu2011347_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1365-2141.2004.04883.x","volume":"125","author":"F Buccisano","year":"2004","unstructured":"Buccisano F, Rossi FM, Venditti A, Del Poeta G, Cox MC, Abbruzzese E et al. CD90\/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. Br J Haematol 2004; 125: 203\u2013212.","journal-title":"Br J Haematol"},{"key":"BFleu2011347_CR31","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1126\/science.1164390","volume":"322","author":"A Colmone","year":"2008","unstructured":"Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA . Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008; 322: 1861\u20131865.","journal-title":"Science"},{"key":"BFleu2011347_CR32","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029\u20131035.","journal-title":"Lancet Oncol"},{"key":"BFleu2011347_CR33","first-page":"1570","volume":"7","author":"F Lanza","year":"1993","unstructured":"Lanza F, Bi S, Castoldi G, Goldman JM . Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia. Leukemia 1993; 7: 1570\u20131575.","journal-title":"Leukemia"},{"key":"BFleu2011347_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/sj.leu.2403649","volume":"19","author":"W Eisterer","year":"2005","unstructured":"Eisterer W, Jiang X, Christ O, Glimm H, Lee KH, Pang E et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 2005; 19: 435\u2013441.","journal-title":"Leukemia"},{"key":"BFleu2011347_CR35","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/jnci\/djk150","volume":"99","author":"X Jiang","year":"2007","unstructured":"Jiang X, Saw KM, Eaves A, Eaves C . Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007; 99: 680\u2013693.","journal-title":"J Natl Cancer Inst"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2011347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011347","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:40:40Z","timestamp":1648737640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2011347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,9]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["BFleu2011347"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.347","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,9]]},"assertion":[{"value":"6 June 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr JJWM Janssen and Dr GJ Ossenkoppele received research support and honoraria for consultancy from Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}